JP Morgan Chase’s Astrana Health ASTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.37M | Buy |
56,191
+588
| +1% | +$13.9K | ﹤0.01% | 4384 |
|
|
2025
Q4 | $1.38M | Sell |
55,603
-8,695
| -14% | -$231K | ﹤0.01% | 4381 |
|
|
2025
Q3 | $1.82M | Sell |
64,298
-27,903
| -30% | -$756K | ﹤0.01% | 4152 |
|
|
2025
Q2 | $2.29M | Buy |
92,201
+22,030
| +31% | +$620K | ﹤0.01% | 3810 |
|
|
2025
Q1 | $2.18M | Sell |
70,171
-93,361
| -57% | -$3.11M | ﹤0.01% | 3808 |
|
|
2024
Q4 | $5.16M | Buy |
163,532
+94,268
| +136% | +$4.48M | ﹤0.01% | 3310 |
|
|
2024
Q3 | $4.01M | Sell |
69,264
-1,144
| -2% | -$56.2K | ﹤0.01% | 3379 |
|
|
2024
Q2 | $2.86M | Buy |
70,408
+2,235
| +3% | +$88.6K | ﹤0.01% | 3480 |
|
|
2024
Q1 | $2.86M | Sell |
68,173
-22,117
| -24% | -$863K | ﹤0.01% | 3550 |
|
|
2023
Q4 | $3.46M | Buy |
90,290
+2,704
| +3% | +$90K | ﹤0.01% | 3411 |
|
|
2023
Q3 | $2.7M | Sell |
87,586
-4,572
| -5% | -$158K | ﹤0.01% | 3320 |
|
|
2023
Q2 | $2.91M | Buy |
92,158
+8,825
| +11% | +$303K | ﹤0.01% | 3268 |
|
|
2023
Q1 | $3.04M | Buy |
83,333
+11,940
| +17% | +$418K | ﹤0.01% | 3213 |
|
|
2022
Q4 | $2.11M | Buy |
71,393
+3,468
| +5% | +$111K | ﹤0.01% | 3516 |
|
|
2022
Q3 | $2.65M | Buy |
67,925
+9,063
| +15% | +$415K | ﹤0.01% | 3242 |
|
|
2022
Q2 | $2.27M | Buy |
58,862
+5,303
| +10% | +$202K | ﹤0.01% | 3434 |
|
|
2022
Q1 | $2.6M | Buy |
53,559
+9,293
| +21% | +$479K | ﹤0.01% | 3553 |
|
|
2021
Q4 | $3.25M | Buy |
44,266
+17,784
| +67% | +$1.46M | ﹤0.01% | 3414 |
|
|
2021
Q3 | $2.41M | Sell |
26,482
-122,772
| -82% | -$10.4M | ﹤0.01% | 3643 |
|
|
2021
Q2 | $9.38M | Sell |
149,254
-13,946
| -9% | -$516K | ﹤0.01% | 2483 |
|
|
2021
Q1 | $4.42M | Buy |
163,200
+1,282
| +0.8% | +$30.8K | ﹤0.01% | 3076 |
|
|
2020
Q4 | $2.96M | Buy |
161,918
+41,768
| +35% | +$751K | ﹤0.01% | 3208 |
|
|
2020
Q3 | $2.09M | Buy |
120,150
+74,294
| +162% | +$1.28M | ﹤0.01% | 3197 |
|
|
2020
Q2 | $756K | Sell |
45,856
-3,983
| -8% | -$62.7K | ﹤0.01% | 3663 |
|
|
2020
Q1 | $644K | Buy |
49,839
+47,767
| +2,305% | +$779K | ﹤0.01% | 3692 |
|
|
2019
Q4 | $38K | Sell |
2,072
-6,897
| -77% | -$114K | ﹤0.01% | 5204 |
|
|
2019
Q3 | $158K | Buy |
8,969
+7,236
| +418% | +$124K | ﹤0.01% | 4730 |
|
|
2019
Q2 | $28K | Buy |
1,733
+922
| +114% | +$16.7K | ﹤0.01% | 5377 |
|
|
2019
Q1 | $15K | Sell |
811
-39
| -5% | -$748 | ﹤0.01% | 5468 |
|
|
2018
Q4 | $17K | Buy |
850
+80
| +10% | +$1.5K | ﹤0.01% | 5353 |
|
|
2018
Q3 | $17K | Sell |
770
-4,374
| -85% | -$92.1K | ﹤0.01% | 5445 |
|
|
2018
Q2 | $133K | Buy |
+5,144
| New | +$88.1K | ﹤0.01% | 4735 |
|
Other funds holding ASTH
VPM
3C
VCM
6CM
JP Morgan Chase's ASTH Position: Q1 2026 in Review
JP Morgan Chase increased its Astrana Health (ASTH) stake by 1.1% in Q1 2026, buying an estimated $13.9K and bringing the position to 56,191 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #4384.
JP Morgan Chase first reported a position in ASTH in Q2 2018 and has held it in 32 quarters since. The position peaked at $9.38M in Q2 2021. 171 funds tracked by Wall St. Rank hold ASTH as of Q1 2026.
- JP Morgan Chase held 56,191 shares of Astrana Health worth $1.37M as of Q1 2026.
- JP Morgan Chase bought 588 Astrana Health shares in Q1 2026, an estimated $13.9K.
- Astrana Health made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4384 holding.
- JP Morgan Chase first reported a position in Astrana Health in Q2 2018 and has held it in 32 quarters since.
- JP Morgan Chase's Astrana Health position peaked at $9.38M in Q2 2021.
- 171 funds tracked by Wall St. Rank held Astrana Health as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.